Congress Park Capital’s iShares Biotechnology ETF IBB Stock Holding History

Congress Park Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,101	Closed	-$648K	–	121
2023 Q2	$648K	Sell	5,101 -75	-1%	-$9.74K	0.32%	67
2023 Q1	$669K	Sell	5,176 -705	-12%	-$92.3K	0.35%	64
2022 Q4	$772K	Sell	5,881 -320	-5%	-$41.4K	0.45%	57
2022 Q3	$725K	Sell	6,201 -30	-0.5%	-$3.73K	0.42%	52
2022 Q2	$733K	Sell	6,231 -1,195	-16%	-$142K	0.45%	58
2022 Q1	$968K	Sell	7,426 -1,015	-12%	-$132K	0.49%	54
2021 Q4	$1.29M	Buy	8,441 +677	+9%	+$105K	0.63%	41
2021 Q3	$1.25M	Buy	7,764 +2,810	+57%	+$473K	0.64%	45
2021 Q2	$811K	Buy	4,954 +406	+9%	+$62.5K	0.41%	58
2021 Q1	$685K	Buy	4,548 +455	+11%	+$72.3K	0.38%	64
2020 Q4	$620K	Buy	4,093 +1,336	+48%	+$191K	0.37%	60
2020 Q3	$373K	Buy	2,757 +400	+17%	+$54.3K	0.23%	70
2020 Q2	$322K	Buy	+2,357	New	+$300K	0.25%	72

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Congress Park Capital's IBB Position: Q3 2023 in Review

Congress Park Capital sold out of iShares Biotechnology ETF (IBB) in Q3 2023, closing a stake of 5,101 shares — an estimated $648K sold.

Congress Park Capital first reported a position in IBB in Q2 2020 and held it in 13 quarters. The position peaked at $1.29M in Q4 2021. 832 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

Congress Park Capital reported no remaining iShares Biotechnology ETF position as of Q3 2023 after selling out during the quarter.
Congress Park Capital sold 5,101 iShares Biotechnology ETF shares in Q3 2023, an estimated $648K.
Congress Park Capital first reported a position in iShares Biotechnology ETF in Q2 2020 and held it in 13 quarters.
Congress Park Capital's iShares Biotechnology ETF position peaked at $1.29M in Q4 2021.
832 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on Congress Park Capital's 13F filing for Q3 2023, filed 13 Oct 2023.